2 penny stocks with a strong buy and a plus of over 200% on the horizon
Let’s talk about the risk and the bigger picture. It is a fair time as the great risk – posed by the COVID-19 pandemic – is finally receding thanks to the ongoing vaccination program. COVID leaves an economy that was forced to stall a year ago during a major expansion fueled by deregulation policies. While the new Biden administration is busy reversing many Trump policies, the economy is recovering, at least for now. And that puts us at risk. A period of economic growth and recovery is a forgiving time for venture investing as overall economic growth tends to lift everything up. Two JPMorgan strategists came out recently suggesting that market fundamentals are still solid and that the small to mid-cap sector will continue to rise. Initially, on the general terms and conditions, quant strategist Dubravko Lakos-Bujas wrote: “Although the recent technical sell-off and short squeeze are getting a lot of attention, we believe the positive macro setup, improvement in fundamentals and COVID-19 outlook is the strength the US are consumers and reflation remains the bigger forces at work. This should not only drive the share capital higher, but it also remains favorable for a further rotation towards economic reopening … ”Building on this, Eduardo Lecubarr, head of the small / mid-cap strategy team, now sees opportunities for investors, especially with regard to this on the lesser value stocks. « We hold to our view that if you are willing to go against the grain, 2021 will be a stock picker paradise with great money making opportunities … Many macro indicators fell in January, but SMid caps and stocks are in General continued to rise. » Lecubarr bem noticed. And if you tend to look at risky small to mid-cap stocks, then you will be drawn to penny stocks. The risk associated with these games puts the faint of heart off, as very real issues like weak fundamentals or overwhelming headwinds could be masked by the low stock prices. How should investors approach a potential penny stock investment? By aligning with the analyst community. These experts bring in-depth knowledge of the industries they cover and extensive experience. With that in mind, according to Wall Street analysts, we used the TipRanks database to find two compelling penny stocks. Both tickers have a strong buy consensus rating and could rise by over 200% in the coming year. CNS Pharmaceuticals (CNSP) We’re starting out with CNS Pharmaceuticals, a biotechnology company focused on the treatment of glioblastoma, a class of aggressive tumors that attack the plexus and spinal cord. These cancers are rare, but almost always fatal, and the CNS is working on a new therapy that will help cross the blood-brain barrier more effectively to attack glioblastoma. The flagship of the CNS, berubicin, is an anthracycline, a potent class of chemotherapy drugs derived from strains of Streptomyces bacteria that are used to treat a wide variety of cancers. Berubicin is the first drug in its class to show promise against glioblastoma cancer. The drug candidate has completed its Phase 1 clinical trial, in which 44% of the patients showed a clinical response. That number included one patient who had a « sustained full response » defined as a demonstrated lack of detectable cancer. Following the success of the Phase 1 study, the CNS applied for and received FDA approval g for his application for a new investigational medicinal product. This gives the company the opportunity to conduct a phase 2 study in adult patients. This is an important next step in the development of the drug. CNS plans to start the intermediate trial in the first quarter of 21. Based on the company’s potential for glioblastoma assets and a share price of $ 2.22, several analysts believe now is the time to buy. Among the bulls is Brooklines 5-star analyst Kumaraguru Raja, who is bullish on CNSP stocks. “Until now, the inability of anth Racycline to cross the blood-brain barrier prevented its use in the treatment of brain tumors. Berubicin is the first anthracycline that crosses the blood-brain barrier in adults and has access to brain tumors. Berubicin has promising clinical data in a Phase 1 study in recurrent glioblastoma (rGBM) and has the FDA’s orphan drug designation for the treatment of malignant gliomas. We are modeling berubicin’s approval for the treatment of recurrent glioblastoma in 2025 based on the Phase 2 data with a 55% chance of success for approval. We anticipate peak sales of $ 533 million in 2032, ”said Raja. The CNS pipeline also includes WP1244 (novel DNA binding agent), which is 500x more effective than daunorubicin in inhibiting tumor cell proliferation. It is expected to come to the clinic in 2021. In vivo testing in orthotopic models of brain cancer showed high brain uptake of WP1244 and subsequent antitumor activity, ”the analyst added. To that end, Raja rates CNSP as a buy and his $ 10 price target implies room for an impressive upside of 350% over the next 12 months. (To view Raja’s track record, click Si e here.) What does the rest of the street have to say? 3 buys and 1 hold results in a strong buy consensus rating. Given the average target price of $ 8.33, stocks could rise ~ 275% over the coming year. (See CNSP stock analysis on TipRanks) aTyr Pharma (LIFE) Next stock, aTyr Pharma, is focused on inflammatory diseases. Its lead drug candidate, ATYR1923, is a neuropilin-2 (NRP2) agonist that works on the receptor proteins expressed by the NRP2 gene. These pathways are important for cardiovascular development and disease and play a role in the inflammatory lung disease pulmonary sarcoid. In December, the company reported that the drug candidate had completed enrollment in 36 patients in a Phase 1b / 2a clinical trial testing the drug for the treatment of pulmonary sarcoid. The results of the current study are expected in the third quarter of 21 and will be further studies at ATYR1923, Inc. against other forms of inflammatory lung disease. In early January, the company announced the key results of another Phase 2 clinical trial of ATRY1923 – this time in the treatment of patients with severe respiratory disease due to COVID-19. The results were positive and showed that a single dose of ATYR1923 (3 mg / kg) resulted in a mean recovery time of 5.5 days. Overall, 83% of the patients dosed this way recovered in less than a week. The 5-star analyst Zegbeh Jallah reported on LIFE for Roth Capital: “We like the risk profile here with two shots on goal. Updated data from the COVID study are expected in the coming months. It was also recently announced that data from aTyr’s pulmonary sarcoid program will be released in Q3 21. The success of any of these studies could result in doubling or more of the market capital as these opportunities seem to be barely taken into account by investors. “Consistent with its bullish approach, Jallah is rating LIFE shares as buy and its target price of $ 15 suggests an impressive upside of 277% for the year ahead. (To view Jallah’s track record, click here.) Other analysts are on the same page. With 2 additional buy reviews, the word is on the street that LIFE is a strong buy. Additionally, the average price target is $ 13.33, which indicates robust growth of ~ 236% from the current price of $ 3.97. (See LIFE Stock Analysis on TipRanks.) To find great ideas for trading penny stocks at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all of the insights into TipRanks stocks. Disclaimer: The opinions expressed in this article are solely those of the presented analysts. The content is intended to be used for informational purposes only. It is very important that you do your own analysis before making any investment.
Why is the pound sterling so strong?
The demands on these products are consistently high, so the pound keeps increasing. As the UK’s inflation rate is lower than many other countries, purchasing power is therefore higher. This is one reason why the pound exchange rate is strong, and why it is almost always the case.
What is the safest currency?
Yen, Euro and US dollar banknotes of various denominations. The Japanese yen and Swiss franc remain relatively safe bets, Morgan Stanley said on Tuesday, but the investment bank chose the U.S. dollar as the best safe currency in what remains of turbulent 2020.
Will the pound ever recover?
Pound sterling is being pushed by international investment bank and lender BNP Paribas to ramp up and offset its recent losses before the end of 2020, but not before it continues to fall in the short term as Brexit fears re-rise. … Above: GBP is the worst performing currency in 2020.
What will be the strongest currency in the world in 2020?
Top 10: Strongest World Currencies 2020
- # 1 Kuwaiti Dinar [1 KWD = 3.27 USD] …
- # 2 Bahraini Dinar [1 BHD = 2.65 USD] …
- # 3 Omani Rial [1 OMR = USD 2.60] …
- Jordanian Dinar No. 4 [1 JOD = 1.41 USD] …
- # 5 pounds sterling [1 GBP = 1.30 USD] …
- # 6 Cayman Islands Dollar [1 KYD = 1.20 USD] …
- # 7 euros [1 EUR = 1.18 USD] …
- # 8 Swiss Francs [1 CHF = 1.10 USD]
Why is the dollar so weak?
Since oil and many other commodities are valued in dollars, lower demand also means lower demand for dollars. … Historically, stock market volatility increases in the months leading up to an election (albeit less in recent years), which weakens investor demand for dollars.
Is the USD likely to fall?
« We forecast another 5 to 10% decline through 2021 as the Fed allows the US economy to get hot. » ING chief economist Carsten Brzeski said in a research note Thursday, and the Dutch lender sees the euro well on the way to changing hands at $ 1.25.
Why is the USD value falling?
Control your money | Wed 1 p.m. ET, February. The dollar slide has been underway since spring. The currency fell sharply after hitting more than three-year highs in March as the global economic collapse caused by the pandemic and the accompanying turmoil in financial markets sparked a global turmoil in the dollar.
Will the USD weaken in 2020?
The US currency is near its lowest level in 27 months and is down about 11% from its 2020 high against a basket of its peers, with Goldman Sachs, UBS and Societe Generale forecasting further losses among banks. … The greenback is overvalued against other major currencies by about 10%, they said.
What’s the strongest? Has the pound ever been against the dollar?
The pound-to-dollar exchange rate peaked on March 6, 1972 at $ 2.649. This remains the strongest rate the pound has seen against the USD since it went public in 1971 in the UK government.
How strong is the pound today?
Today the pound is up 0.64% against the dollar to 1.3011 USD and 0.38% against the euro to 1.1958 EUR.
What’s the weakest the pound has ever been?
The weakest pound compared to the euro on December 30, 2008 was € 1.02. This was during the global financial crisis. At the time, the UK banking system was fragile and needed government support to stave off the collapse.
Why is the British pound more expensive than the dollar?
For example, if the pound is strong against the dollar, you will get more dollars for your pounds. The stronger the pound, the cheaper it is to buy things overseas. The same goes for things that you buy in the UK and that come from abroad.
Will GBP USD go up?
GBP / USD Mid-Day Outlook With 1.3608 support intact, further advance is expected. On the upside, the break at 1.3758 will extend the entire uptrend from 1.1409 to 61.8%. The forecast of 1.1409 to 1.3482 will increase from 1.2675 to 1.3956 next.
Why is GBP so weak?
GBP / EUR exchange rates continue to suffer from the uncertainty surrounding Brexit. The pound-euro exchange rate hit a 23-month low this week. This is largely due to the higher likelihood of a no deal. The more likely a no-deal is the potential outcome of Brexit, the weaker one would expect the pound sterling to be.
Why is the GBP rising?
The pound was owed to the twists and turns of the Brexit trade negotiations as the UK and EU face an agreement by the end of the year. The pound and euro hit their highest levels in over two years as the UK and the European Union may be optimistic about reaching a trade deal that coincides with a weakening dollar.